Kiromic BioPharma Reports Patient 4 in Deltacel-01 Clinical Trial Reaches 10-Month Progression-Free Survival
1. Kiromic reports positive efficacy results in its Deltacel-01 trial. 2. Fourth patient shows favorable outcomes after 10 months.
FAQ
Why Bullish?
Positive clinical trial results can boost investor confidence, similar to past biotech successes.
How important is it?
Clinical trial data is critical for biotech firms, often resulting in price movements.
Why Long Term?
Efficacy data from ongoing trials could lead to future FDA approvals, affecting long-term valuation.